Testing a new ointment for atopic dermatitis in healthy adults and patients
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new ointment called CU-10101. It will first be tested in healthy volunteers to check safety, and then in people with atopic dermatitis (eczema) to see how well it works for mild to moderate symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old (or 18 to 65 if you have eczema) and in good general health.
- Your body mass index (BMI) is between 18 and 27, and you weigh at least 50 kg (men) or 45 kg (women).
- You have mild to moderate eczema covering 5% to 40% of your body (not counting scalp, face, genitals, or skin folds).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use birth control during the study and for 3 months after.
- You have not used certain eczema treatments or other investigational products recently, and you agree to avoid alcohol, smoking, and certain medications during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new ointment (HL-300) designed to treat mild-to-moderate atopic dermatitis (a chronic skin condition causing itching and inflammation). You would apply it to affected skin areas to see if it safely reduces symptoms.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.